PMID- 33754891
OWN - NLM
STAT- MEDLINE
DCOM- 20211011
LR  - 20211011
IS  - 1552-695X (Electronic)
IS  - 1534-7354 (Print)
IS  - 1534-7354 (Linking)
VI  - 20
DP  - 2021 Jan-Dec
TI  - Immunomodulatory Effect of Green Tea Treatment in Combination with Low-dose 
      Chemotherapy in Elderly Acute Myeloid Leukemia Patients with 
      Myelodysplasia-related Changes.
PG  - 15347354211002647
LID - 10.1177/15347354211002647 [doi]
LID - 15347354211002647
AB  - Green tea (GT) treatment was evaluated for its effect on the immune and 
      antineoplastic response of elderly acute myeloid leukemia patients with 
      myelodysplasia-related changes (AML-MRC) who are ineligible for aggressive 
      chemotherapy and bone marrow transplants. The eligible patients enrolled in the 
      study (n = 10) received oral doses of GT extract (1000 mg/day) alone or combined 
      with low-dose cytarabine chemotherapy for at least 6 months and/or until 
      progression. Bone marrow (BM) and peripheral blood (PB) were evaluated monthly. 
      Median survival was increased as compared to the control cohort, though not 
      statistically different. Interestingly, improvements in the immunological profile 
      of patients were found. After 30 days, an activated and cytotoxic phenotype was 
      detected: GT increased total and naive/effector CD8(+) T cells, 
      perforin(+)/granzyme B(+) natural killer cells, monocytes, and classical 
      monocytes with increased reactive oxygen species (ROS) production. A reduction in 
      the immunosuppressive profile was also observed: GT reduced TGF-beta and IL-4 
      expression, and decreased regulatory T cell and CXCR4(+) regulatory T cell 
      frequencies. ROS levels and CXCR4 expression were reduced in bone marrow CD34(+) 
      cells, as well as nuclear factor erythroid 2-related factor 2 (NRF2) and 
      hypoxia-inducible factor 1alpha (HIF-1alpha) expression in biopsies. Immune modulation 
      induced by GT appears to occur, regardless of tumor burden, as soon as 30 days 
      after intake and is maintained for up to 180 days, even in the presence of 
      low-dose chemotherapy. This pilot study highlights that GT extracts are safe and 
      could improve the immune system of elderly AML-MRC patients.
FAU - Calgarotto, Andrana K
AU  - Calgarotto AK
AD  - University of Campinas, Campinas, Sao Paulo, Brazil.
FAU - Longhini, Ana L
AU  - Longhini AL
AD  - University of Campinas, Campinas, Sao Paulo, Brazil.
FAU - Pericole de Souza, Fernando V
AU  - Pericole de Souza FV
AD  - University of Campinas, Campinas, Sao Paulo, Brazil.
FAU - Duarte, Adriana S Santos
AU  - Duarte ASS
AD  - University of Campinas, Campinas, Sao Paulo, Brazil.
FAU - Ferro, Karla P
AU  - Ferro KP
AD  - University of Campinas, Campinas, Sao Paulo, Brazil.
FAU - Santos, Irene
AU  - Santos I
AD  - University of Campinas, Campinas, Sao Paulo, Brazil.
FAU - Maso, Victor
AU  - Maso V
AD  - University of Campinas, Campinas, Sao Paulo, Brazil.
FAU - Olalla Saad, Sara T
AU  - Olalla Saad ST
AD  - University of Campinas, Campinas, Sao Paulo, Brazil.
FAU - Torello, Cristiane Okuda
AU  - Torello CO
AUID- ORCID: 0000-0002-1611-020X
AD  - University of Campinas, Campinas, Sao Paulo, Brazil.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Integr Cancer Ther
JT  - Integrative cancer therapies
JID - 101128834
RN  - 0 (Tea)
RN  - 04079A1RDZ (Cytarabine)
SB  - IM
MH  - Aged
MH  - CD8-Positive T-Lymphocytes
MH  - Cytarabine
MH  - Humans
MH  - *Leukemia, Myeloid, Acute/drug therapy
MH  - Pilot Projects
MH  - *Tea
PMC - PMC7995304
OTO - NOTNLM
OT  - acute myeloid leukemia with myelodysplasia-related changes
OT  - green tea
OT  - immune response
OT  - polyphenols
OT  - reactive oxygen species
COIS- Declaration of Conflicting Interests: The author(s) declared no potential 
      conflicts of interest with respect to the research, authorship, and/or 
      publication of this article.
EDAT- 2021/03/24 06:00
MHDA- 2021/10/12 06:00
PMCR- 2021/03/23
CRDT- 2021/03/23 12:20
PHST- 2021/03/23 12:20 [entrez]
PHST- 2021/03/24 06:00 [pubmed]
PHST- 2021/10/12 06:00 [medline]
PHST- 2021/03/23 00:00 [pmc-release]
AID - 10.1177_15347354211002647 [pii]
AID - 10.1177/15347354211002647 [doi]
PST - ppublish
SO  - Integr Cancer Ther. 2021 Jan-Dec;20:15347354211002647. doi: 
      10.1177/15347354211002647.